traitement des cancers ORL. Cancer Radiother.
2005; 9: 31-6.
13 The department of Veteran Affairs Laryngeal
Cancer Study Group. Induction chemotherapy
plus radiation compared with surgery plus
radiation in patients with advanced laryngeal
cancer. N Engl J Med. 1991; 324: 1685-90.
14 Janot F, Rhein B, Koka V. Préservation laryngée
par chimiothérapie première. À propos
de l’expérience de deux centres du GETTEC
dans les cancers de l’endolarynx traités entre
1985 et 1995. Ann Otolaryngol Chir Cervicofac.
2002; 119: 12-20.
15 Bernier J, Vermorken JB, Koch WM. Adjuvant
therapy in patients with resected poor-risk
head and neck cancer. J Clin Oncol. 2006; 24:
2629-35.
16 Hitt R, Grau J, Lopez-Pousa A, Berrocal A,
García-Giron C, Belon J et al. Randomized
phase II/III clinical trial of induction chemotherapy
(ICT) with either cisplatin/5-fluorouracil
(PF) or docetaxel/cisplatin/5-fluorouracil
(TPF) followed by chemoradiotherapy
(CRT) vs. crt alone for patients (pts) with
unresectable locally advanced head and neck
cancer (LAHNC). J Clin Oncol. 2006; 24(18 s):
283s (abst. 5515).
17 Forastiere AA, Goepfert H, Maor M, Pajak TF,
Weber R, Morrison W et al. Concurrent chemotherapy
and radiotherapy for organ preservation
in advanced laryngeal cancer.
N Engl J Med. 2003; 349: 2091-8.
18 Bensadoun RJ, Benezery K, Dassonville O,
Magne N, Poissonnet G, Ramaioli A et al.
French multicenter phase III randomized
study testing concurrent twice-a-day radiotherapy
and cisplatin/5-fluorouracil chemotherapy
(BiRCF) in unresectable pharyngeal
carcinoma: Results at 2 years (FNCLCC-GORTEC).
Int J Radiat Oncol Biol Phys. 2006; 64:
983-94.
19 Bernier J, Cooper JS, Pajak TF, Van Glabbeke M,
Bouhris J, Forastière A et al. Defining risk levels
in locally advanced head and neck cancers:
a comparative analysis of concurrent postoperative
radiation plus chemotherapy trials of the
EORTC (#22931) and RTOG (# 9501). Head
Neck. 2005; 27: 843-50.
20 Janot F, De Raucourt D, Castaing M, Bardet E,
Dolivet G, Bensadoun R et al. Re-irradiation
combined with chemotherapy after salvage
surgery in head and neck carcinoma: a randomized
trial from the GETTEC and GORTEC
groups. J Clin Oncol. 2006; 24(18 s): 282s
(abst. 5508).
21 Dassonville O, Formento JL, Francoual M,
Ramaioli A, Santini J, Schneider M et al.
Expression of epidermal growth factor receptor
and survival in upper aerodigestive tract
cancer. J Clin Oncol. 1993; 11: 1873-8.
22 Magné N, Pivot X, Bensadoun RJ, Guardiola E,
Poissonnet G, Dassonville O et al. The relationship
of epidermal growth factor receptor
level to the prognosis of unresectable pharyngeal
cancer patients treated by chemo-radiotherapy.
Eur J Cancer. 2001; 37: 2169-77.
23 Harari PM, Huang S. Head and neck cancer as
a clinical model for molecular targeting of
therapy: combining EGFR blockade with
radiation. Int J Radiat Oncol Biol Phys. 2001;
49: 427-33.
24 Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB et al. Radiotherapy plus
cetuximab for squamous-cell carcinoma of
the head and neck. N Engl J Med. 2006; 354:
567-78.
25 Baselga J, Trigo JM, Bourhis J, Tortochaux J,
Cortes-Funes H, Hitt R et al. Phase II multicenter
study of the antiepidermal growth
factor receptor monoclonal antibody cetuximab
in combination with platinum-based
chemotherapy in patients with platinumrefractory
metastatic and/or recurrent squamous
cell carcinoma of the head and neck.
J Clin Oncol. 2005; 23: 5568-77.
26 Herbst RS, Arquette M, Shin DM, Dicke K,
Vokes EE, Azarnia N et al. Phase II multicenter
study of the epidermal growth factor
receptor antibody cetuximab and cisplatin
for recurrent and refractory squamous cell
carcinoma of the head and neck. J Clin Oncol.
2005; 23: 5578-87.
27 Rivera S, Keryer C, Busson P, Maingon P. Les
carcinomas du nasopharynx: de la biologie à
la clinique. Cancer Radiother. 2005; 9: 55-68.
28 Julieron M, Temam S. Récidives locorégionales
des cancers ORL: place de la chirurgie.
Bull Cancer. 2004; 91: 863-9.
29 Posner MR, Wirth LJ. Cetuximab and radiotherapy
for head and neck cancer. N Engl J Med.
2006; 354: 634-6.
Poissonnet G, Benezery K, Peyrade F, Bozec A, Bensadoun RJ, Marcy PY et al.
tome
2005; 9: 31-6.
13 The department of Veteran Affairs Laryngeal
Cancer Study Group. Induction chemotherapy
plus radiation compared with surgery plus
radiation in patients with advanced laryngeal
cancer. N Engl J Med. 1991; 324: 1685-90.
14 Janot F, Rhein B, Koka V. Préservation laryngée
par chimiothérapie première. À propos
de l’expérience de deux centres du GETTEC
dans les cancers de l’endolarynx traités entre
1985 et 1995. Ann Otolaryngol Chir Cervicofac.
2002; 119: 12-20.
15 Bernier J, Vermorken JB, Koch WM. Adjuvant
therapy in patients with resected poor-risk
head and neck cancer. J Clin Oncol. 2006; 24:
2629-35.
16 Hitt R, Grau J, Lopez-Pousa A, Berrocal A,
García-Giron C, Belon J et al. Randomized
phase II/III clinical trial of induction chemotherapy
(ICT) with either cisplatin/5-fluorouracil
(PF) or docetaxel/cisplatin/5-fluorouracil
(TPF) followed by chemoradiotherapy
(CRT) vs. crt alone for patients (pts) with
unresectable locally advanced head and neck
cancer (LAHNC). J Clin Oncol. 2006; 24(18 s):
283s (abst. 5515).
17 Forastiere AA, Goepfert H, Maor M, Pajak TF,
Weber R, Morrison W et al. Concurrent chemotherapy
and radiotherapy for organ preservation
in advanced laryngeal cancer.
N Engl J Med. 2003; 349: 2091-8.
18 Bensadoun RJ, Benezery K, Dassonville O,
Magne N, Poissonnet G, Ramaioli A et al.
French multicenter phase III randomized
study testing concurrent twice-a-day radiotherapy
and cisplatin/5-fluorouracil chemotherapy
(BiRCF) in unresectable pharyngeal
carcinoma: Results at 2 years (FNCLCC-GORTEC).
Int J Radiat Oncol Biol Phys. 2006; 64:
983-94.
19 Bernier J, Cooper JS, Pajak TF, Van Glabbeke M,
Bouhris J, Forastière A et al. Defining risk levels
in locally advanced head and neck cancers:
a comparative analysis of concurrent postoperative
radiation plus chemotherapy trials of the
EORTC (#22931) and RTOG (# 9501). Head
Neck. 2005; 27: 843-50.
20 Janot F, De Raucourt D, Castaing M, Bardet E,
Dolivet G, Bensadoun R et al. Re-irradiation
combined with chemotherapy after salvage
surgery in head and neck carcinoma: a randomized
trial from the GETTEC and GORTEC
groups. J Clin Oncol. 2006; 24(18 s): 282s
(abst. 5508).
21 Dassonville O, Formento JL, Francoual M,
Ramaioli A, Santini J, Schneider M et al.
Expression of epidermal growth factor receptor
and survival in upper aerodigestive tract
cancer. J Clin Oncol. 1993; 11: 1873-8.
22 Magné N, Pivot X, Bensadoun RJ, Guardiola E,
Poissonnet G, Dassonville O et al. The relationship
of epidermal growth factor receptor
level to the prognosis of unresectable pharyngeal
cancer patients treated by chemo-radiotherapy.
Eur J Cancer. 2001; 37: 2169-77.
23 Harari PM, Huang S. Head and neck cancer as
a clinical model for molecular targeting of
therapy: combining EGFR blockade with
radiation. Int J Radiat Oncol Biol Phys. 2001;
49: 427-33.
24 Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB et al. Radiotherapy plus
cetuximab for squamous-cell carcinoma of
the head and neck. N Engl J Med. 2006; 354:
567-78.
25 Baselga J, Trigo JM, Bourhis J, Tortochaux J,
Cortes-Funes H, Hitt R et al. Phase II multicenter
study of the antiepidermal growth
factor receptor monoclonal antibody cetuximab
in combination with platinum-based
chemotherapy in patients with platinumrefractory
metastatic and/or recurrent squamous
cell carcinoma of the head and neck.
J Clin Oncol. 2005; 23: 5568-77.
26 Herbst RS, Arquette M, Shin DM, Dicke K,
Vokes EE, Azarnia N et al. Phase II multicenter
study of the epidermal growth factor
receptor antibody cetuximab and cisplatin
for recurrent and refractory squamous cell
carcinoma of the head and neck. J Clin Oncol.
2005; 23: 5578-87.
27 Rivera S, Keryer C, Busson P, Maingon P. Les
carcinomas du nasopharynx: de la biologie à
la clinique. Cancer Radiother. 2005; 9: 55-68.
28 Julieron M, Temam S. Récidives locorégionales
des cancers ORL: place de la chirurgie.
Bull Cancer. 2004; 91: 863-9.
29 Posner MR, Wirth LJ. Cetuximab and radiotherapy
for head and neck cancer. N Engl J Med.
2006; 354: 634-6.
Poissonnet G, Benezery K, Peyrade F, Bozec A, Bensadoun RJ, Marcy PY et al.
tome
